PHAR
Price
$16.28
Change
+$0.07 (+0.43%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.14B
98 days until earnings call
Intraday BUY SELL Signals
SONN
Price
$1.26
Change
-$1.84 (-59.35%)
Updated
Dec 2 closing price
Capitalization
8.6M
Intraday BUY SELL Signals
Interact to see
Advertisement

PHAR vs SONN

Header iconPHAR vs SONN Comparison
Open Charts PHAR vs SONNBanner chart's image
Pharming Group
Price$16.28
Change+$0.07 (+0.43%)
Volume$613
Capitalization1.14B
Sonnet BioTherapeutics Holdings
Price$1.26
Change-$1.84 (-59.35%)
Volume$10.46M
Capitalization8.6M
PHAR vs SONN Comparison Chart in %
PHAR
Daily Signal:
Gain/Loss:
SONN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PHAR vs. SONN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAR is a StrongBuy and SONN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (PHAR: $16.07 vs. SONN: $1.28)
Brand notoriety: PHAR and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAR: 47% vs. SONN: 783%
Market capitalization -- PHAR: $1.09B vs. SONN: $8.6M
PHAR [@Biotechnology] is valued at $1.09B. SONN’s [@Biotechnology] market capitalization is $8.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAR’s FA Score shows that 1 FA rating(s) are green whileSONN’s FA Score has 0 green FA rating(s).

  • PHAR’s FA Score: 1 green, 4 red.
  • SONN’s FA Score: 0 green, 5 red.
According to our system of comparison, PHAR is a better buy in the long-term than SONN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAR’s TA Score shows that 4 TA indicator(s) are bullish while SONN’s TA Score has 2 bullish TA indicator(s).

  • PHAR’s TA Score: 4 bullish, 6 bearish.
  • SONN’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, PHAR is a better buy in the short-term than SONN.

Price Growth

PHAR (@Biotechnology) experienced а -5.79% price change this week, while SONN (@Biotechnology) price change was -69.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

PHAR is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($1.15B) has a higher market cap than SONN($8.6M). PHAR YTD gains are higher at: 59.662 vs. SONN (-12.486). PHAR has higher annual earnings (EBITDA): 29.5M vs. SONN (-13.97M). PHAR has more cash in the bank: 126M vs. SONN (321K). SONN has less debt than PHAR: SONN (68.8K) vs PHAR (128M). PHAR has higher revenues than SONN: PHAR (340M) vs SONN (1M).
PHARSONNPHAR / SONN
Capitalization1.15B8.6M13,311%
EBITDA29.5M-13.97M-211%
Gain YTD59.662-12.486-478%
P/E RatioN/A0.29-
Revenue340M1M34,000%
Total Cash126M321K39,252%
Total Debt128M68.8K186,047%
FUNDAMENTALS RATINGS
SONN: Fundamental Ratings
SONN
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
95
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHARSONN
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
80%
Momentum
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
90%
MACD
ODDS (%)
Bullish Trend 7 days ago
70%
Bearish Trend 7 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
67%
Bearish Trend 7 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
70%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
69%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
83%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PHAR
Daily Signal:
Gain/Loss:
SONN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SNIEX19.45N/A
N/A
BNY Mellon International Equity I
PEGZX21.40N/A
N/A
PGIM Jennison Mid-Cap Growth Z
YOVAX17.34N/A
N/A
Yorktown Small-Cap A
FLUIX30.62N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val I
SVALX6.67N/A
N/A
Federated Hermes Strategic Value Div R6

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
-0.99%
APLM - PHAR
31%
Poorly correlated
-0.79%
ANTX - PHAR
29%
Poorly correlated
+2.86%
ADPT - PHAR
27%
Poorly correlated
-0.80%
IBRX - PHAR
27%
Poorly correlated
-9.13%
ATXS - PHAR
26%
Poorly correlated
-0.16%
More